This is a working overview of systematic review, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
The Tempest (2001) - Boatswain I Dreamt of Bombay (2002) - Bobby Girlfriends (2002) - Guy Hulk (2003) - Soldier Ball & Chain (2004) - Monty War of the Worlds (2005) - Boston Soldier Over There (2005) - Sergeant First Class Neeson Cold Case (2006) - Wes Floyd Veronica Mars (2007) I Gotta Be Better Than Keanu (2007) - Slimy Agent Scrubs (2001–2009) - Dr. Doug Murphy The Beast (2009) - Todd Jaracki
The first submarine not relying on human power for propulsion was the French Plongeur (Diver), launched in 1863, which used compressed air at 1,200 kPa (180 psi). Narcís Monturiol designed the first air-independent and combustion-powered submarine, Ictíneo II, which was launched in Barcelona, Spain in 1864. The submarine became feasible as potential weapon with the development of the Whitehead torpedo, designed in 1866 by British engineer Robert Whitehead, the first practical self-propelled torpedo. The spar torpedo that had been developed earlier by the Confederate States Navy was considered to be impracticable, as it was believed to have sunk both its intended target, and H. L. Hunley, the submarine that deployed it. The Irish inventor John Philip Holland built a model submarine in 1876 and in 1878 demonstrated the Holland I prototype. This was followed by a number of unsuccessful designs. In 1896, he designed the Holland Type VI submarine, which used internal combustion engine power on the surface and electric battery power underwater. Launched on 17 May 1897 at Navy Lt. Lewis Nixon's Crescent Shipyard in Elizabeth, New Jersey, Holland VI was purchased by the United States Navy on 11 April 1900, becoming the Navy's first commissioned submarine, christened USS Holland. Discussions between the English clergyman and inventor George Garrett and the Swedish industrialist Thorsten Nordenfelt led to the first practical steam-powered submarines, armed with torpedoes and ready for military use.
The first published recommendations for protection against radium and radiation in general were made by the British X-ray and Radium Protection Committee and were adopted internationally in 1928 at the first meeting of the International Commission on Radiological Protection (ICRP), following preliminary guidance written by the Röntgen Society. This meeting led to further developments of radiation protection programs coordinated across all countries represented by the commission. Exposure to radium is still regulated internationally by the ICRP, alongside the World Health Organization. The International Atomic Energy Agency (IAEA) publishes safety standards and provides recommendations for the handling of and exposure to radium in its works on naturally occurring radioactive materials and the broader International Basic Safety Standards, which are not enforced by the IAEA but are available for adoption by members of the organization. In addition, in efforts to reduce the quantity of old radiotherapy devices that contain radium, the IAEA has worked since 2022 to manage and recycle disused 226Ra sources. In several countries, further regulations exist and are applied beyond those recommended by the IAEA and ICRP. For example, in the United States, the Environmental Protection Agency-defined Maximum Contaminant Level for radium is 5 pCi/L for drinking water; at the time of the Manhattan Project in the 1940s, the "tolerance level" for workers was set at 0.1 micrograms of ingested radium.
Sources: en.wikipedia.org
== Scientific references == Aller, Raymond D.; Salazar, Vincent (2016), "Microbiology Laboratory Information Systems", Manual of Commercial Methods in Clinical Microbiology, John Wiley & Sons, Inc, pp. 377–385, doi:10.1002/9781119021872.ch20, ISBN 978-1-119-02187-2 Burkhartsmeier, Gary (June 2007), "HIPAA: Where are we now", Research Gate, vol. 39, no. 6, p. 28, PMID 17691704 De Rienzo, Assunta; Cook, Robert W.; Wilkinson, Jeff; Gustafson, Corinne E.; Amin, Waqas; Johnson, Clare E.; Oelschlager, Kristen M.; Maetzold, Derek J.; Stone, John F.; Feldman, Michael D.; Becich, Michael J.; Yeap, Beow Y.; Richards, William G.; Bueno, Raphael (2017-01-01), "Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues", The Journal of Molecular Diagnostics, 19 (1): 65–71, doi:10.1016/j.jmoldx.2016.07.011, PMC 5225306, PMID 27863259 Turgeon, Mary Louise (2015-02-10), "Linne & Ringsrud's Clinical Laboratory Science - E-Book: The Basics and Routine Techniques", Elsevier Health Sciences, ISBN 978-0-323-37061-5 "Association of Pathology Chairs", Academic Pathology. 5: 2374289518788096, vol. 5, 2018-07-09, doi:10.1177/2374289518788096, ISSN 2374-2895, PMC 6039897
Compared to other TCAs, trimipramine is relatively safe in overdose, although it is more dangerous than the selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) but less dangerous than bupropion in cases of overdose.
In addition to these biomarkers, the FDA has approved certain drug-companion diagnostic pairings based on genetic mutations. For example, BRAF-targeted therapies for metastatic melanoma are only indicated for patients whose tumors harbor a BRAF mutation. While these tests are now commonly marketed as essential tools for precision oncology, they remain costly. Moreover, some have been the subject of controversy or misuse. Notable examples include the Duke University cancer fraud scandal and questionable claims surrounding so-called "liquid biopsies."
Sources: en.wikipedia.org
nondisjunction The failure of homologous chromosomes or sister chromatids to segregate properly during cell division. Nondisjunction results in daughter cells that are aneuploid, containing abnormal numbers of one or more specific chromosomes. It may be caused by a variety of factors.
=== Recreational use === Although some studies have reported flupirtine has no addictive properties, there was suggestion that it may possess some miuse potential and liability. There were at least two registered cases of flupirtine misuse. Drug tolerance does not develop in most cases, but has individually occurred. Flupirtine was reported as a novel designer drug in 2025. The effects of flupirtine have been said to be very difficult to describe. They have been reported to include "strong helicopter-like effects at high doses" causing users to have to "walk leaning against a wall", dissociative effects, feelings of euphoria throughout the body, and a very light buzzing sensation. Some have compared it to mephedrone, while others have described the physical bodily sensations as similar to those of MDMA and other entactogens. The drug is said to be able to produce psychosis and mania as adverse effects and to do so more readily than cathinone stimulants. The euphoria produced by flupirtine is said to last 40 to 60 minutes, whereas other effects last all day. The effects are said to convert after 2 hours from stimulant or euphoriant effects into a kind of nootropic effect that affects thinking. The drug is frequently used to enhance the effects of other recreational drugs.
Russia claimed to have taken the village of Shumy, ten kilometers east of Toretsk. Seven people were killed and 36 others were injured in a Russian attack in Vilniansk, Zaporizhzhia Oblast. Three people were killed in separate attacks in Donetsk and Kherson Oblasts. Russian officials claimed that five people, including two children, were killed in a Ukrainian drone strike in Gorodishche, Kursk Oblast.
The 21st Century Cures Act enacted in December 2016 allows researchers to waive the requirement for informed consent when clinical testing "poses no more than minimal risk" and "includes appropriate safeguards to protect the rights, safety, and welfare of the human subject." The probability that a patient may sue researchers who utilize tissues that would typically be discarded is low, but as genetic research becomes more prevalent, this likelihood may increase. Ideally, researchers should obtain informed consent from individuals and aim for transparency in their intended use of the human tissue while protecting the privacy of the donor. CAP and other laboratory accreditation organizations (AO) have additional requirements and protocols for repurposing biospecimens that would otherwise be discarded. In July 2011, an Advance Notice of Proposed Rule Making (ANPRM), entitled "Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators" was published in the Federal Register. The rise in direct-to-consumer (DTC) genetic testing has raised concerns about the secondary use of both patient samples and their data.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.